3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Dementia With Lewy Bodies (DLB)

Conditions

Dementia With Lewy Bodies (DLB)

Trial Timeline

Nov 1, 2007 → Feb 1, 2010

NCT ID

NCT00543855

About 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo

3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo is a phase 2 stage product being developed by Eisai for Dementia With Lewy Bodies (DLB). The current trial status is completed. This product is registered under clinical trial identifier NCT00543855. Target conditions include Dementia With Lewy Bodies (DLB).

What happened to similar drugs?

9 of 20 similar drugs in Dementia With Lewy Bodies (DLB) were approved

Approved (9) Terminated (1) Active (10)

✅E2020 + PlaceboEisaiApproved

✅donepezil hydrochloride (Aricept)EisaiApproved

✅MecobalaminEisaiApproved

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅Risperdal,reminylJohnson & JohnsonApproved

✅ENA713NovartisApproved

✅Rivastigmine Patch 9.5 cm2NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00543855	Phase 2	Completed	Nov 1, 2007	Feb 1, 2010	Dementia With Lewy Bodies (DLB)

Competing Products

20 competing products in Dementia With Lewy Bodies (DLB)

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
Mecobalamin	Eisai	Approved	43
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43